Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0793
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2614
    -0.0008 (-0.06%)
     
  • USD/JPY

    151.3290
    -0.0430 (-0.03%)
     
  • Bitcoin USD

    70,222.02
    -524.43 (-0.74%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

Inovio Pharmaceuticals Inc (INO) Q4 Revenue Grew 3.5% Year-Over-Year

Inovio Pharmaceuticals Inc (NASDAQ:INO) reported its latest quarterly earnings results after the bell Wednesday, with revenue and earnings rising year-over-year.

Inovio Pharmaceuticals Inc (INO)
Inovio Pharmaceuticals Inc (INO)

The pharmaceutical company announced a net loss of $21.5 million, or 24 cents per share, narrower than its year-ago loss of $26.2 million, or 35 cents per share for its fourth quarter. For the full year, the company lost $88.2 million, or $1.08 per basic share, which was wider than the year-ago loss of $73.7 million, or $1.01 per basic share.

Inovio Pharmaceuticals reported total revenue for its fourth quarter of $8.8 million, a 3.5% gain compared to the year-ago quarter of $8.5 million. For the full year, the company’s revenue reached $42.2 million, beating the $35.4 million from the year-ago quarter, rising more than 19% compared to the year-ago quarter.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

The company’s total operating expenses for the quarter were $31.7 million, ahead of the year-ago total of $30.9 million. For the full fiscal year, this figure was $125.9 million, topping the year-ago total operating expenses of $111.6 million.

Inovio Pharmaceutical’s research and development expenses for the quarter came in at $24.6 million, and they were $98.6 million for the fiscal year 2017. In the year-ago period and year, they were $23.9 million and $88.7 million respectively. This increase in expenses was linked with a rise in the company’s headcount.

INO shares were trading flat after the bell.

More From InvestorPlace

Compare Brokers

The post Inovio Pharmaceuticals Inc (INO) Q4 Revenue Grew 3.5% Year-Over-Year appeared first on InvestorPlace.

Advertisement